Therapeutic effect of different rosuvastatin regimens on elderly patients with dyslipidemia
Ning Haishan
An Xuecong
Zhang Daixi
Zhang Boheng
Yao Jiaxue
Zhang Qi
Liu Xiaokun.
Abstract：Objective To compare the efficacy and compliance of different rosuvastatin regimens in elderly patients with dyslipidemia. Methods A total of 168 elderly patients with dyslipidemia who aged 75 years and over cared at Tangshan Gongren Hospital from February 2017 to October 2017 were included in this study. The patients were randomly divided into daily medication group and every-other-day medication group. The daily medication group was initiated on 10mg rosuvastatin daily and every-other-day medication group was given rosuvastatin 10 mg every other day. The serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL) and peripheral blood lipoprotein-related phospholipase A2 (Lp-PLA2) levels were examined before and after the treatment which lasted for at least 6 months in the daily and daily medication groups. The change rate of LDL-C, the rate of LDL-C reach target goal and the change rate of Lp-PLA2 in the two groups of patients were calculated. The number of adverse reactions and the types of adverse reactions in the two groups were recorded. A comparison and analysis was made on the compliance of the daily medication group and the every-other-day medication group. Results A total of 168 patients were enrolled in the study at the start of the study, aged 75~89 years, mean (78.26±2.98) years old. At the end of the trial, 49 patients were excluded due to poor compliance, and finally 119 patients completed the trial. There were 52 patients in the daily medication group (n=52) and 67 patients in the medication group every other day (n=67). After 6 months of rosuvastatin treatment, the levels of TC, TG and LDL-C in the two groups were significantly lower than those before administration (P<0.05). The daily dose of LDL-C decreased by 35.96%. LDL-C decreased by 32.68% every other day, and the difference was not statistically significant (P>0.05). The LDL-C compliance rate was 76.9% after 6 months of oral rosuvastatin treatment in the daily medication group and the next day. 71.6%, but the difference was not statistically significant (P>0.05). The peripheral blood Lp-PLA2 levels in the daily medication group and the next day medication group decreased by 57.81% and 57.37%, respectively, and the difference was not statistically significant (P>0.05). Among the patients in the daily medication group, 61.90% (52/84 cases) had good compliance, and 79.76% (67/84 cases) had good compliance in the next day. The difference was statistically significant (P<0.05). Conclusions Taking rosuvastatin every other day and rosuvastatin daily have similar effects in lowering LDL-C and Lp-PLA2 levels, and taking rosuvastatin every other day reduces the cost and improves the patient's Medication compliance.
Keywords：RosuvastatinAdvanced ageEvery-other-day medicationEfficacyCompliance
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 360-362,366 )